Bernard Roubert

Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation

Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples

Nutritional immunity: transition metals at the pathogen–host interface

Advances in metal-induced oxidative stress and human disease

Design of iron chelators with therapeutic application

A role of PIEZO1 in iron metabolism in mice and humans

Sickle-cell disease

Oxidative Stress in Cancer

Pathogenesis and management of iron toxicity in thalassemia

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism

Identification and transcriptome analysis of erythroblastic island macrophages

How I treat transfusional iron overload

Iron-Deficiency Anemia

How I manage patients with atypical microcytic anaemia

Iron overload in thalassemia: different organs at different rates

Iron and Cancer

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

Response of iron overload to deferasirox in rare transfusion‐dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with  -thalassemia major

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Continued improvement in myocardial T2* over two years of deferasirox therapy in  -thalassemia major patients with cardiac iron overload

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial